Arrhythmogenic Right Ventricular Cardiomyopathy Pathology
- Author: Allen Patrick Burke, MD; Chief Editor: Allen Patrick Burke, MD more...
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a primary disease of heart muscle that results in fibrofatty replacement of the right ventricle and the subepicardial region of the left ventricle. Patients are at high risk for ventricular tachyarrhythmias and sudden death (see the image below).
Although ARVC was initially described in the right ventricle, examination of the heart in autopsy cases of ARVC, microscopically or with sensitive imaging techniques, has established that most patients with ARVC have biventricular involvement.
The left ventricular involvement is typically subepicardial, and the changes are related more to fibrosis than to fat or fibrofatty infiltration, although at times the changes are probably similar to those seen in the right ventricle. However, because the right ventricle is relatively thin, the subepicardial nature of disease is difficult to appreciate in imaging studies and has only infrequently been investigated at autopsy. Atrial involvement appears not to have been adequately investigated.
Previously, investigators postulated that ARVC begins in the right ventricle and progresses to biventricular involvement and heart failure. However, newer imaging techniques have revealed that left ventricular involvement is typical from the onset.
Some patients with ARVC develop heart failure and intractable arrhythmias and are treated with heart transplantation. A subset of these patients carries the clinical diagnosis of idiopathic dilated cardiomyopathy. In such patients, the pathologic diagnosis of ARVC is made initially on finding fibrofatty replacement on histologic sections of the recipient's explanted heart.
The etiology of arrhythmogenic right ventricular cardiomyopathy (ARVC) is unknown. The presence of inflammatory infiltrates in most cases that have been seen at autopsy has led to the theory that it is a resolving myocarditis. Families have been described with phenotypic alterations ranging from myocarditis to fibrofatty cardiac infiltrates, and imaging studies have demonstrated a progression from myocarditis to ARVC.
Family studies have suggested that ARVC is caused by genetic alterations in desmosomal proteins, especially plakoglobin and desmoplakin.[5, 6, 7, 8, 9] One family study demonstrated desmosomal mutations in just less than 20% of patients. Because desmosomal mutations are seen in other cardiac conditions, the link between the desmosome and ARVC has been questioned. ARVC is possibly an inflammatory process modulated by genetic influences in desmosome-related proteins.
The prevalence of arrhythmogenic right ventricular cardiomyopathy (ARVC) has been estimated at 1:2500 to 1:5000. In series of sudden cardiac death, this condition represents the cause of 2-5% of deaths in young adults, with higher incidences in exertional deaths and in certain regions of Europe. (Approximately three quarters of sudden deaths related to ARVC are exertional.) ARVC is a relatively new entity, and its incidence worldwide is not yet established.
ARVC is generally limited to the young, especially males younger than 40 years, although the disease has been described up to the ninth decade. This condition is extremely uncommon under the age of 10 years.
Because autopsy studies are skewed toward fatal arrhythmogenic right ventricular cardiomyopathy (ARVC) and by consent for autopsy, it has been assumed that ARVC is uniformly lethal. The clinical diagnosis has been hampered by the nonspecificity of electrocardiographic and imaging findings. However, with improvements in cardiac MRI and computed tomography (CT) scanning, the clinical diagnosis has become more precise.
Studies of families with ARVC have suggested that with antiarrhythmic treatment, including the implantation of defibrillators, the prognosis may be improved. Young age, a family history of juvenile sudden death, QRS dispersion greater than or equal to 40 ms, T-wave inversion, left ventricular involvement, ventricular tachycardia, syncope, and previous cardiac arrest are the major risk factors for adverse prognosis. Preparticipation screening for sport eligibility has been proven to be effective in detecting asymptomatic patients and sport disqualification has saved lives; sudden death in young athletes has substantially declined.
A study by Groeneweg et al aimed to define long-term outcome of arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) in a transatlantic cohort of 1001 individuals. The study concluded that long-term outcome was favorable in diagnosed and treated ARVD/C index-patients and family members.[14, 15]
The primary symptoms of arrhythmogenic right ventricular cardiomyopathy (ARVC) are related to arrhythmias and conduction disturbances. However, the condition is frequently symptomless, with the first manifestation being sudden, unexpected death. Moreover, symptoms, hemodynamics, and electrocardiographic findings are relatively nonspecific, although advances in cardiac imaging, especially magnetic resonance imaging (MRI), have increased the reproducibility of clinical diagnosis.
The diagnosis of ARVC is generally made pathologically at autopsy or at examination of explanted hearts at orthotopic heart transplantation. Endomyocardial biopsy is unreliable, as sampling the apical septum does not typically reveal diagnostic material, and biopsies of the septal endomyocardium may not show the characteristic lesions.
At autopsy, the major differential diagnosis includes normal fat deposits in the right ventricle, and subepicardial scars of ischemic origin. Adipose tissue is normally present in the right ventricle, especially in the anterior wall toward the apex, but no associated fibrosis or myocyte changes exist. In the left ventricle, subepicardial scars can be associated with ischemic heart disease, especially if there is embolization of thromboembolic material from epicardial coronary lesions.
In cases of unexplained exertional death in young adults, submitting multiple sections of ventricular septum and right ventricle to exclude arrhythmogenic forms of cardiomyopathy is reasonable, as ARVC most typically involves the right ventricle and may be difficult to see grossly; additionally, hypertrophic cardiomyopathy may involve the interventricular septum without obvious grossly abnormalities. Because both of these entities often cause exertional death, taking multiple sections of right ventricle and ventricular septum in cases of exertional deaths is prudent.
Several clinical criteria for the diagnosis of ARVC have been proposed, including those of the Working Groups on Myocardial and Pericardial Disease and Arrhythmias of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the World Heart Federation (in 2000, with a revision in 2002).
In general, immunohistochemistry (IHC) is not useful in the diagnosis arrhythmogenic right ventricular cardiomyopathy (ARVC). Some investigators have postulated that diffuse loss of desmosomal proteins, as seen immunohistochemically, is suggestive of the diagnosis of ARVC. These proteins include connexin-43 and plakoglobin.
At autopsy, the major differential diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC) includes normal fat deposits in the right ventricle, and subepicardial scars of ischemic origin. Adipose tissue is normally present in the right ventricle, especially in the anterior wall toward the apex, but no associated fibrosis or myocyte changes exist. In the left ventricle, subepicardial scars can be associated with ischemic heart disease, especially if there is embolization of thromboembolic material from epicardial coronary lesions.
In cases of arrhythmogenic right ventricular cardiomyopathy (ARVC), the typical findings at autopsy include areas of thinning of the right ventricle, with fibrofatty change, in areas where fat is not normally found (outflow region, posterior wall) (see the image below). Pathologic findings at autopsy are wide ranging, depending on the stage and extent of the disease.
Autopsy studies from patients who die suddenly with the disease demonstrate biventricular involvement in most cases, with subepicardial left ventricular involvement and right ventricular fibrofatty infiltration.
Left ventricular involvement grossly is that of scars in the subepicardial region, randomly throughout the ventricle; the fat is difficult to appreciate, and often the fibrosis is more conspicuous (see the image above). The ventricular septum is relatively spared. Aneurysms of the right ventricle, while well described in the literature (triangle of dysplasia), are present in only a minority of patients. In a small proportion of cases, gross abnormalities may in some cases be minimal, with the diagnosis made only microscopically.
Histologically, the ventricle in arrhythmogenic right ventricular cardiomyopathy (ARVC) may show a range of changes, with the dominant feature being fatty or fibrofatty replacement of the myocardium (see the image below). It may appear randomly "moth-eaten," with destruction of the normal myocytes via inflammation, scarring, and fat replacement; show patchy areas of full-thickness loss of myocytes and replacement by fibrofatty tissues; or show inflammation composed of lymphocytes and macrophages, with only rare myocyte necrosis.
The myocytes in the involved areas appear attenuated, with loss of cross-striations and areas of myofibrillar loss imparting a "bubbly" appearance. The changes are nonspecific, as fat may be a component of ischemic scarring and myocyte vacuolization may be seen in other forms of cardiomyopathy, as well as inflammatory infiltrates.
Lobo FV, Silver MD, Butany J, Heggtveit HA. Left ventricular involvement in right ventricular dysplasia/cardiomyopathy. Can J Cardiol. 1999 Nov. 15(11):1239-47. [Medline].
Sen-Chowdhry S, Syrris P, Ward D, Asimaki A, Sevdalis E, McKenna WJ. Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation. 2007 Apr 3. 115(13):1710-20. [Medline].
Burke AP, Farb A, Tashko G, Virmani R. Arrhythmogenic right ventricular cardiomyopathy and fatty replacement of the right ventricular myocardium: are they different diseases?. Circulation. 1998 Apr 28. 97(16):1571-80. [Medline].
Basso C, Thiene G, Corrado D, Angelini A, Nava A, Valente M. Arrhythmogenic right ventricular cardiomyopathy. Dysplasia, dystrophy, or myocarditis?. Circulation. 1996 Sep 1. 94(5):983-91. [Medline].
Bauce B, Basso C, Rampazzo A, et al. Clinical profile of four families with arrhythmogenic right ventricular cardiomyopathy caused by dominant desmoplakin mutations. Eur Heart J. 2005 Aug. 26(16):1666-75. [Medline].
Dokuparti MV, Pamuru PR, Thakkar B, Tanjore RR, Nallari P. Etiopathogenesis of arrhythmogenic right ventricular cardiomyopathy. J Hum Genet. 2005. 50(8):375-81. [Medline].
Fidler LM, Wilson GJ, Liu F, Cui X, Scherer SW, Taylor GP, et al. Abnormal connexin43 in arrhythmogenic right ventricular cardiomyopathy caused by plakophilin-2 mutations. J Cell Mol Med. 2009 Oct. 13(10):4219-28. [Medline].
Rampazzo A, Nava A, Malacrida S, et al. Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet. 2002 Nov. 71(5):1200-6. [Medline]. [Full Text].
Syrris P, Ward D, Evans A, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in the desmosomal gene desmocollin-2. Am J Hum Genet. 2006 Nov. 79(5):978-84. [Medline]. [Full Text].
Zhang M, Tavora F, Li L, Fowler D, Zhao Z, Burke A. Arrhythmogenic right ventricular cardiomyopathy: reassessing the link with the desmosome. Pathology. December 2012. 44:596-604. [Medline].
Francés RJ. Arrhythmogenic right ventricular dysplasia/cardiomyopathy. A review and update. Int J Cardiol. 2006 Jun 28. 110(3):279-87. [Medline].
Ferreira AC, Garcia SA, Pasquale MA, Canoniero MJ, Peter A. Arrhythmogenic right ventricular dysplasia in the elderly. Heart Dis. 2003 Nov-Dec. 5(6):393-6. [Medline].
Groeneweg JA, Bhonsale A, James CA, et al. Clinical Presentation, Long-Term Follow-Up, and Outcomes of 1001 Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patients and Family Members. Circ Cardiovasc Genet. 2015 Jun. 8 (3):437-46. [Medline].
Boggs W. Long-Term Outcomes Favorable for Arrhythmogenic Dysplasia/Cardiomyopathy. Reuters Health Information. Available at http://www.medscape.com/viewarticle/843616. April 24, 2015; Accessed: October 27, 2015.
Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation. 1996 Mar 1. 93(5):841-2. [Medline].
Corrado D, Fontaine G, Marcus FI, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: need for an international registry. Study Group on Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy of the Working Groups on Myocardial and Pericardial Disease and Arrhythmias of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the World Heart Federation. Circulation. 2000 Mar 21. 101(11):E101-6. [Medline].
Hamid MS, Norman M, Quraishi A, et al. Prospective evaluation of relatives for familial arrhythmogenic right ventricular cardiomyopathy/dysplasia reveals a need to broaden diagnostic criteria. J Am Coll Cardiol. 2002 Oct 16. 40(8):1445-50. [Medline].
Asimaki A, Tandri H, Huang H, et al. A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy. N Engl J Med. 2009 Mar 12. 360(11):1075-84. [Medline].
Burke AP, Robinson S, Radentz S, Smialek J, Virmani R. Sudden death in right ventricular dysplasia with minimal gross abnormalities. J Forensic Sci. 1999 Mar. 44(2):438-43. [Medline].